An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

Affiliations

• ¹ Clínica Universidad de Navarra, Pamplona, Spain.
• ² Evidence Synthesis & Decision Modeling, PRECISIONheor, Vancouver, Canada.
• ³ Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
• ⁴ Department of Haematology, University Hospital Leuven, Leuven, Belgium.
• ⁵ Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
• ⁶ Bristol Myers Squibb, Princeton, NJ, USA.
• ⁷ Bristol Myers Squibb, Uxbridge, UK.
• ⁸ Bristol Myers Squibb, Dublin, Ireland.